Therapeutic potential of recombinant human type XVII collagen in wound healing and bullous pemphigoid: From bench to bedside
RHCXVII has the capacity to promote HPKC growth and adherence. In clinical applications, it has been demonstrated to accelerate wound healing in patients with bullous diseases (BD), thereby reducing the risk of subsequent secondary infection. Its potential as an adjunct treatment for wound repair in diseases such as BD merits further investigation.
Authors
- Jiajia Li (ORCID: https://orcid.org/0009-0007-5380-2604)
- Lin Zhou (ORCID: https://orcid.org/0000-0002-2549-2721)
- Suqin Wang (ORCID: https://orcid.org/0000-0003-1725-6902)
- Ruzhi Zhang (ORCID: https://orcid.org/0000-0001-8292-0270)
- Tingting Jiang (ORCID: https://orcid.org/0000-0002-3242-249X)
- Yuxia Fang
- Haihang Li (ORCID: https://orcid.org/0000-0003-1564-5808)
- Linfeng Li (ORCID: https://orcid.org/0000-0002-8736-6464)
- Zhiqiang Zhang (ORCID: https://orcid.org/0000-0002-5122-4923)
- Zeyu Huang (ORCID: https://orcid.org/0009-0006-2898-8278)
Institutions
- Wannan Medical College (CN)
- Soochow University (CN)
- Jiangsu University of Technology (CN)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.ejps.2025.107031
- Citations
- 6
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 8.83